Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
09:20am, Tuesday, 05'th Aug 2025
Neuronetics (STIM) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.33 per share a year ago.
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
04:30pm, Monday, 04'th Aug 2025
MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transf
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
08:32am, Wednesday, 30'th Jul 2025
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world's largest TMS outcomes dataset Real-world data showing NeuroStar is effective in adolescen
Neuronetics Appoints New Chief Financial Officer
07:30am, Tuesday, 15'th Jul 2025
Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succe
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00pm, Thursday, 19'th Jun 2025
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company's ongoing commitment to clinical innovation and excellence NeuroStar, a Silver Sponsor at CTMSS, will also pr
Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes
04:30pm, Monday, 02'nd Jun 2025
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of tran
Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript
09:57am, Tuesday, 06'th May 2025
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer St
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Tuesday, 06'th May 2025
Neuronetics (STIM) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.27 per share a year ago.
Neuronetics Reports First Quarter 2025 Financial and Operating Results
07:10am, Tuesday, 06'th May 2025
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 05'th May 2025
MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
08:31am, Monday, 31'st Mar 2025
Policy update increases access for millions covered by Evernorth Health Services Policy update increases access for millions covered by Evernorth Health Services
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
11:45pm, Saturday, 29'th Mar 2025
Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite re
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results
04:30pm, Thursday, 27'th Mar 2025
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial result
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet
10:55am, Tuesday, 18'th Mar 2025
The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
